OS Therapies Says OST-HER2 Shows Statistically Significant Survival Gain at 2.5 Years in Osteosarcoma Patients
OS Therapies is set to report that its lead immunotherapy candidate, OST-HER2, produced a statistically significant overall survival benefit at 2.5 years in patients with fully resected pulmonary metastatic osteosarcoma. Treated patients recorded a 75% survival rate at 2.5 years, with no additional deaths reported since the two-year readout. The co…